Back to Newsroom

Corbus Pharmaceuticals Expands Clinical Development of Resunab™ with a Phase 2 Trial for the Treatment of Rare Disease Dermatomyositis

NORWOOD, MA — (Marketwired) — 06/05/15 — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases, announced today that its Phase 2 clinical study withResunab™ for the treatment of skin-predominant dermatomyositis is open for enrollment.

Click here to read more